<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allison Vidimos, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd Stultz, DDS, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            June K Robinson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H11115527">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients with cutaneous squamous cell carcinoma (cSCC) or basal cell carcinoma (BCC), disease remains limited to the skin and is successfully managed with local therapy, such as excision, lesion destruction, or irradiation of the primary lesion. However, in 3 to 7 percent of patients with cSCC and in rare individuals with BCC, locoregional or distant metastases occur, resulting in an increased risk for mortality and the need for alternative approaches to therapy [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         The evaluation for regional and distant metastases in patients with cSCC or BCC will be reviewed here. The clinical features and treatment of cSCC and BCC are discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16225.html" rel="external">
          "Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5339.html" rel="external">
          "Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13713.html" rel="external">
          "Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">
          "Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13724.html" rel="external">
          "Treatment of basal cell carcinomas at high risk for recurrence"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19785703">
         <span class="h1">
          CUTANEOUS SQUAMOUS CELL CARCINOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The identification of patients at increased risk for metastasis and, concordantly, the most appropriate work-up for metastatic disease are important components of the management of patients with cutaneous squamous cell carcinoma (cSCC) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1144235623">
         <span class="h2">
          General considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on the approach to the evaluation for metastatic disease are limited, contributing to the absence of definitive recommendations on the indications for investigative tests and the selection of appropriate studies. In general, clinical assessment by physical examination is considered sufficient for the evaluation of most patients with cSCC, whereas those with tumors who exhibit clinical and/or pathologic high-risk features may need further evaluation with imaging studies [
         <a href="#rid5">
          5
         </a>
         ]. According to the 2022 National Comprehensive Cancer Network (NCCN) guidelines, the definition of high-risk cSCC based on risk factors for local recurrence, metastasis, or death is as follows [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-risk cSCC
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lesions of
         <strong>
          any size
         </strong>
         located on the head, neck, hands, feet, pretibia, and anogenital area
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lesions &gt;2 to 4 cm located on the trunk or extremities (excluding pretibia, hands, and feet)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recurrent tumor
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Histopathologically acantholytic (adenoid), adenosquamous (showing mucin production), or metaplastic (carcinosarcomatous) subtypes, with perineural invasion
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Very high-risk cSCC
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lesions &gt;4 cm on
         <strong>
          any location
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Histopathologically poorly differentiated tumor, desmoplastic cSCC, &gt;6 mm in thickness or invasion beyond the subcutaneous fat
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Perineural invasion – Tumor cells within the nerve sheath of a nerve lying deeper than the dermis or ≥0.1 mm
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lymphatic or vascular involvement
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11115543">
         <span class="h2">
          Locoregional evaluation
         </span>
        </p>
        <p class="headingAnchor" id="H2391301909">
         <span class="h3">
          Cutaneous metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infrequently, cSCC can metastasize to the skin. Cutaneous metastases present as multiple small, erythematous papules or nodules that can be ulcerated and crusted. In-transit cutaneous metastases with a linear distribution have been reported in a few patients, most of whom were immunosuppressed [
         <a href="#rid7">
          7
         </a>
         ]. Cutaneous metastases with a dermatomal distribution ("zosteriform cutaneous metastases"), likely due to extensive perineural invasion or retrograde lymphatic spreading of tumor cells, have been very rarely reported in immunosuppressed, as well as immunocompetent, patients [
         <a href="#rid8">
          8-10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3507623479">
         <span class="h3">
          Nodal metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymph nodes are the most common sites for metastasis of cSCC, and regardless of the presence or absence of high-risk features, all patients diagnosed with invasive cSCC should undergo regional lymph node palpation at the time of diagnosis and during post-treatment follow-up. (See
         <a class="medical medical_review" href="/z/d/html/5339.html" rel="external">
          "Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)", section on 'Follow-up'
         </a>
         .)
        </p>
        <p>
         The impact of sentinel lymph node (SLN) biopsy, which has been used to evaluate lymph node status in select patients with high-risk squamous cell carcinoma (SCC), remains uncertain. (See
         <a class="local">
          'Patients without palpable lymph nodes'
         </a>
         below and
         <a class="local">
          'Evaluation for distant metastases'
         </a>
         below and
         <a class="local">
          'Sentinel lymph node biopsy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1815448441">
         <span class="h4">
          Regional lymph node palpation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The selection of sites for palpation is based upon knowledge of the pathways for lymphatic drainage  (
         <a class="graphic graphic_figure graphicRef69528 graphicRef64606" href="/z/d/graphic/69528.html" rel="external">
          figure 1A-B
         </a>
         ). Lymphatic drainage on the head is complex, and lesions in close proximity to one another may drain to different lymph node basins. Common initial sites for metastasis from lesions on the face and scalp include [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nose and cheek lesions – Submandibular nodes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lip and anterior mouth lesions – Submental nodes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Auricular lesions – Posterior auricular nodes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Posterior scalp lesions – Occipital nodes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anterior scalp, forehead, temple lesions – Parotid nodes
        </p>
        <p>
        </p>
        <p>
         The cervical lymph nodes are additional potential sites of metastasis and also should be palpated in all patients with head or neck lesions.
        </p>
        <p>
         In addition to palpation for enlarged regional lymph nodes, all patients should receive a complete skin examination that includes palpation of the skin and soft tissue near the tumor. Papules or nodules in the tumor vicinity or between the tumor and a regional lymph node basin may represent in transit metastases  (
         <a class="graphic graphic_picture graphicRef60608" href="/z/d/graphic/60608.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid11">
          11,12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2824139">
         <span class="h4">
          Patients with palpable lymph nodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         When an enlarged lymph node is detected on palpation, we typically refer the patient for lymph node biopsy via fine needle aspiration (FNA) [
         <a href="#rid13">
          13
         </a>
         ]. Alternatively, the lymph node may be surgically removed for pathologic examination.
        </p>
        <p>
         If the FNA or surgical pathology results are positive for metastatic disease, further evaluation with radiologic imaging is indicated. Radiologic imaging provides information on the size, number, and location of involved lymph nodes, which are necessary for disease staging  (
         <a class="graphic graphic_table graphicRef110946" href="/z/d/graphic/110946.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         If the cytology of a head or neck nodule that is clinically suggestive of an enlarged lymph node is negative for metastatic disease, re-evaluation of the site via radiologic imaging, repeat FNA, or open surgical biopsy to confirm the benign or malignant nature of the nodule is appropriate [
         <a href="#rid14">
          14
         </a>
         ]. Enlarged lymph nodes on the trunk or extremities that are negative for metastatic disease are typically re-evaluated via open surgical biopsy [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2824146">
         <span class="h4">
          Patients without palpable lymph nodes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Definitive guidelines for the investigation for metastatic disease beyond lymph node palpation in patients with cSCC have not been established. In studies of patients with head and neck cancer, palpation has been shown to have a false-negative rate for the detection of lymph node metastases of 15 to 30 percent when compared with radiologic imaging or nodal dissection [
         <a href="#rid15">
          15-20
         </a>
         ]. Hence, it is conceivable that a similar scenario may occur in some patients with cSCC. (See
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer", section on 'Imaging studies'
         </a>
         .)
        </p>
        <p>
         Factors that often lead us to proceed with imaging studies for subclinical nodal disease in patients with cSCC who do not have palpable lymph nodes include [
         <a href="#rid21">
          21,22
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors larger than 2 cm
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors located near major nerves in the head or neck
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In transit metastases
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors invading deep structures (muscle, bone, cartilage)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic signs or symptoms suggestive of extracutaneous involvement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histopathologic or clinical findings (eg, neurologic signs or symptoms) suggestive of perineural invasion of a large nerve trunk (ie, a nerve with an anatomic name)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple high-risk features  (
         <a class="graphic graphic_table graphicRef83683" href="/z/d/graphic/83683.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Perineural invasion, which can be detected on histopathologic examination, suspected due to the presence of sensory or motor neurologic symptoms or seen on radiologic studies in advanced cases, portends an increased risk for metastasis [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         In a survey of Mohs surgeons, perineural invasion was the most commonly reported reason for considering radiologic imaging in patients with high-risk SCC [
         <a href="#rid25">
          25
         </a>
         ]. Adenosquamous, spindle cell, or poorly differentiated SCCs are most likely to exhibit perineural invasion [
         <a href="#rid13">
          13,26,27
         </a>
         ]. The facial and trigeminal nerves are most frequently affected [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         In a single institution study, patients receiving radiologic imaging had a 50 percent lower risk of developing nodal metastases (13 versus 30 percent) and any disease-related outcome (20 versus 42 percent) compared with patients who did not undergo imaging studies [
         <a href="#rid29">
          29
         </a>
         ]. In a subsequent study, almost one-fifth of 99 T2b/T3 primary cSCCs in a high-stage cohort had evidence of metastases at the time of primary tumor treatment, and management was altered in almost one-third of the cohort based on imaging results [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11115550">
         <span class="h4">
          Choice of imaging study
         </span>
         <span class="headingEndMark">
          —
         </span>
         Computed tomography (CT) is often used for the evaluation of regional lymph node status in patients with cSCC [
         <a href="#rid25">
          25
         </a>
         ]. Other radiologic studies utilized include magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound (US), and ultrasound-guided fine needle aspiration cytology (USG-FNAC). Comparative studies on the use of these modalities for the evaluation for locoregional metastases in patients with cSCC are lacking. Thus, much of the information used to guide study selection is based upon information from studies in head and neck cancer and other malignancies.
        </p>
        <p>
         In a 2007 meta-analysis of 17 studies comparing US, USG-FNAC, CT, and MRI in the detection of lymph node metastases among patients with head and neck SCC, the pooled sensitivity and specificity were 87 percent (95% CI 76-93) and 86 percent (95% CI 74-93), respectively, for US; 80 percent (95% CI 57-92) and 98 percent (95% CI 93-100), respectively, for USG-FNAC; 81 percent (95% CI 68-90) and 76 percent (95% CI 62-87), respectively, for CT; and 81 percent (95% CI 65-91) and 63 percent (95% CI 43-80), respectively, for MRI [
         <a href="#rid31">
          31
         </a>
         ]. These results suggest that the diagnostic accuracy in the detection of metastatic lymph nodes in patients with head and neck cancer is similar for all imaging modalities, with US and USG-FNAC having a higher specificity.
        </p>
        <p>
         Consultation with a radiologist may assist with the selection of the most appropriate study to evaluate specific targeted features. Patient tolerance for specific radiologic modalities and test availability also influence test selection. (See
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer", section on 'Diagnosis and staging evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H222944">
         <span class="h5">
          Computed tomography and magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest the use of CT or MRI for the evaluation for nodal disease. CT and MRI are the most common initial radiologic tests used in the assessment of patients with cSCC [
         <a href="#rid25">
          25
         </a>
         ]. Both CT and MRI can detect lymph node metastases. In a 2012 meta-analysis of 16 studies evaluating the diagnostic accuracy of MRI in the detection of cervical lymph node metastases in patients with head and neck SCC, the pooled sensitivity and specificity of MRI were 76 percent (95% CI 70-82 percent) and 86 percent (95% CI 73-93 percent) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Radiologic imaging with CT or MRI is also useful for evaluating tumor extent for preoperative planning and staging in patients with large or deeply invasive lesions. CT is superior to MRI for the evaluation of skull base invasion, involvement of cartilage, and bone erosion or destruction, while MRI is more useful for detecting perineural invasion, providing soft tissue contrast, defining tissue planes, and identifying bone marrow infiltration in the absence of significant osseous destruction [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         CT is less expensive than MRI, and, in many clinical settings, CT is more easily attained. The properties of MRI prohibit use in patients with certain implanted devices. The contraindications for MRI are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/113084.html" rel="external">
          "Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging", section on 'Assessing implants, devices, or foreign bodies for MRI'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19786131">
         <span class="h5">
          Positron emission tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of PET in the setting of malignancy has risen with increasing test availability and decreasing test cost. PET functions through the detection of the accelerated uptake of intravenously administered fluorodeoxyglucose that occurs in tumor cells. A beneficial feature of PET is its ability to detect metastases in sites of fibrosis, necrosis, and dense scarring related to radiotherapy, areas that may be difficult to assess with other studies [
         <a href="#rid34">
          34
         </a>
         ]. However, false-positive results are common with PET due to the incidental detection of metabolically active inflammatory, infectious, or other lesions.
        </p>
        <p>
         Another, less favorable feature of PET is the poor spatial resolution attained with this study. The integration of PET and CT (PET/CT) has addressed this issue through providing improved anatomic correlation.
        </p>
        <p>
         Study data on the use of PET for the evaluation of lymph nodes specifically in patients with cSCC are limited to a retrospective study of 12 patients with cSCC in which PET detected lymph node metastases in three out of nine patients with high-risk SCC [
         <a href="#rid35">
          35
         </a>
         ]. In head and neck cancer, the value of PET for the detection of occult metastases is uncertain; PET/CT may be more beneficial. (See
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer", section on 'PET and integrated PET/CT'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H222951">
         <span class="h5">
          Ultrasound and ultrasound-guided fine needle aspiration cytology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The results of studies that suggest that USG-FNAC may be useful for the evaluation of lymph nodes in patients with vulvar SCC and head and neck cancer raise the question of whether the procedure may be of value for lymph node surveillance in patients with cSCC [
         <a href="#rid36">
          36,37
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer", section on 'Fine needle aspiration biopsy'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 44 patients with primary SCC of the vulva, USG-FNAC was more sensitive (80 versus 58 percent) and specific (100 versus 75 percent) than CT for the diagnosis of lymph node metastases [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a subsequent meta-analysis of three studies examining the performance of USG-FNAC in the detection of nodal metastases in patients with head and neck cancer, the pooled sensitivity and specificity of USG-FNAC were 80 percent (95% CI 57-92) and 98 percent (95% CI 93-100), respectively [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         US spares the radiation exposure associated with CT, but the utility of this procedure may be compromised by operator-dependent accuracy, difficulty in following specific lesions over time, and reduced ability to detect metastases to deep lymph nodes. The last item may be less of a concern in cSCC, which typically metastasizes to superficial lymph nodes. However, additional studies are necessary to determine the role of USG-FNAC for surveillance in this population.
        </p>
        <p class="headingAnchor" id="H757711047">
         <span class="h4">
          Sentinel lymph node biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         SLN biopsy is a minimally invasive procedure that identifies the lymph node or lymph nodes most likely to harbor micrometastases using lymphoscintigraphy to detect uptake of radiolabeled colloid and blue dye injected at the site of the tumor. The role of SLN biopsy in the management and outcome of patients with high-risk cSCC has not been evaluated in randomized trials. Data from observational studies are insufficient to determine whether early detection of microscopic metastatic disease has a beneficial effect on patient survival [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13713.html" rel="external">
          "Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma", section on 'Sentinel lymph node biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19785516">
         <span class="h2">
          Evaluation for distant metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         The lungs, liver, brain, and bone are the most frequent sites for distant metastases of cSCC. We typically evaluate for distant metastases in patients with lesions that have a very high risk for metastasis, known locoregional metastases, or signs or symptoms suggestive of distant disease.
        </p>
        <p>
         CT, PET, and PET/CT have been used for whole-body imaging for the evaluation for distant metastases. The comparative efficacy of these studies for the detection of distant metastases has not been evaluated in cSCC. Data on the utility of these studies in head and neck cancer are available separately. (See
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer", section on 'Evaluation for distant metastases'
         </a>
         .)
        </p>
        <p>
         Systemic therapy for metastatic SCC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19784616">
         <span class="h1">
          BASAL CELL CARCINOMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compared with cutaneous squamous cell carcinoma (cSCC), there is an even greater lack of data on the evaluation for metastatic disease in patients with basal cell carcinoma (BCC). This is likely related to the rarity of systemic involvement; the risk of metastasis for BCC is estimated to be between 0.05 to 0.1 percent [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13724.html" rel="external">
          "Treatment of basal cell carcinomas at high risk for recurrence", section on 'Locally advanced tumors/metastatic disease'
         </a>
         .)
        </p>
        <p>
         Metastatic BCC most frequently involves the regional lymph nodes, lungs, bone, skin, and liver [
         <a href="#rid41">
          41
         </a>
         ]. Large lesions (particularly those over 10 cm
         <sup>
          2
         </sup>
         ) and tumors that invade deep structures, such as cartilage, skeletal muscle, or bone, are most likely to metastasize [
         <a href="#rid39">
          39
         </a>
         ]. Perineural invasion, aggressive histologic growth patterns, and longstanding lesions are additional risk factors for metastasis [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         As in cSCC, CT and MRI may be used for the evaluation for metastases and local tissue invasion. The value of positron emission tomography (PET) and sentinel lymph node (SLN) biopsy in BCC is uncertain. PET detected lymph node metastases in a patient with BCC [
         <a href="#rid42">
          42
         </a>
         ] but was unable to detect primary BCCs in three out of six patients in one series, raising questions about the sensitivity of the test for BCC [
         <a href="#rid43">
          43
         </a>
         ]. In a study of 22 patients with metastatic BCC treated with
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         , PET/CT images tended to demonstrate more disease in bone and soft tissue compared with contrast-enhanced CT images; contrast-enhanced CT images tended to demonstrate more disease in the lung [
         <a href="#rid44">
          44
         </a>
         ]. PET/CT was also used to demonstrate response to vismodegib; a decrease in maximum standardized uptake value was associated with improved progression-free survival and overall survival [
         <a href="#rid45">
          45
         </a>
         ]. Detection of lymph node metastasis via SLN biopsy in a patient with pathologic evidence for lymphatic invasion in a primary excision specimen of a BCC has been reported [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Systemic therapy for advanced BCC is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2898765550">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120260.html" rel="external">
          "Society guideline links: Nonmelanoma skin cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H959028">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cutaneous squamous cell carcinoma
         </strong>
         – Most patients with cutaneous squamous cell carcinoma (cSCC) can be evaluated for locoregional metastatic disease through skin examination and regional lymph node palpation. If features associated with an elevated risk for metastasis are present, further evaluation with radiologic imaging may be indicated. (See
         <a class="local">
          'Locoregional evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with palpable lymph nodes
         </strong>
         – Enlarged regional lymph nodes detected on physical examination should be sampled via fine needle aspiration (FNA) or surgical excision in patients with cSCC. If disease is identified in lymph nodes, radiologic imaging to determine the size, number, and location of involved lymph nodes should be performed. (See
         <a class="local">
          'Patients with palpable lymph nodes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients without palpable lymph nodes
         </strong>
         – The indications for further evaluation of lymph node status when lymph nodes appear normal on physical examination are less certain. We typically proceed with radiologic imaging in patients with clinical or histopathologic features that suggest an elevated risk for metastasis. We suggest the use of CT or MRI for the initial evaluation for nodal disease. (See
         <a class="local">
          'Patients without palpable lymph nodes'
         </a>
         above and
         <a class="local">
          'Choice of imaging study'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The value of sentinel lymph node (SLN) biopsy in high-risk cSCC is unknown. It has not been evaluated in randomized trials and data from observational studies are insufficient to determine whether early detection of microscopic metastatic disease improves patient survival. (See
         <a class="local">
          'Sentinel lymph node biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Basal cell carcinoma
         </strong>
         – There are few data to guide the use of imaging studies for patients with basal cell carcinoma (BCC) at high risk of recurrence. CT or MRI studies may be used for the evaluation for metastases and deep local tumor invasion. The value of positron emission tomography (PET) and SLN biopsy in BCC is uncertain. (See
         <a class="local">
          'Basal cell carcinoma'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/13724.html" rel="external">
          "Treatment of basal cell carcinomas at high risk for recurrence"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Khan K, Mykula R, Kerstein R, et al. A 5-year follow-up study of 633 cutaneous SCC excisions: Rates of local recurrence and lymph node metastasis. J Plast Reconstr Aesthet Surg 2018; 71:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genders RE, Osinga JAJ, Tromp EE, et al. Metastasis Risk of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients and Immunocompetent Patients. Acta Derm Venereol 2018; 98:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013; 68:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humphreys TR, Shah K, Wysong A, et al. The role of imaging in the management of patients with nonmelanoma skin cancer: When is imaging necessary? J Am Acad Dermatol 2017; 76:591.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2022 Squamous Cell Skin Cancer. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf (Accessed on July 05, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carucci JA, Martinez JC, Zeitouni NC, et al. In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg 2004; 30:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crevier-Sorbo G, Cernii A, Cepoi A. Metastatic zosteriform cutaneous squamous cell carcinoma. CMAJ 2021; 193:E1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato N, Aoyagi S, Sugawara H, Mayuzumi M. Zosteriform and epidermotropic metastatic primary cutaneous squamous cell carcinoma. Am J Dermatopathol 2001; 23:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fearfield LA, Nelson M, Francis N, Bunker CB. Cutaneous squamous cell carcinoma with zosteriform metastases in a human immunodeficiency virus-infected patient. Br J Dermatol 2000; 142:573.
          </a>
         </li>
         <li class="breakAll">
          Nguyen TH, Joon J. Squamous cell carcinoma. In: Cancer of the Skin, Rigel DS, Friedman R, Dzubow LM, et al (Eds), Elsevier Saunders, 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma JH, Wu A, Veness M, et al. In-Transit Metastasis From Squamous Cell Carcinoma. Dermatol Surg 2016; 42:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 2011; 64:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller SJ, Alam M, Andersen J, et al. Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw 2010; 8:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman M, Mafee MF, Pacella BL Jr, et al. Rationale for elective neck dissection in 1990. Laryngoscope 1990; 100:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali S, Tiwari RM, Snow GB. False-positive and false-negative neck nodes. Head Neck Surg 1985; 8:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anzai Y, Brunberg JA, Lufkin RB. Imaging of nodal metastases in the head and neck. J Magn Reson Imaging 1997; 7:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien CJ, Soong SJ, Urist MM, Maddox WA. Is modified radical neck dissection only a staging procedure? Cancer 1987; 59:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Righi PD, Kopecky KK, Caldemeyer KS, et al. Comparison of ultrasound-fine needle aspiration and computed tomography in patients undergoing elective neck dissection. Head Neck 1997; 19:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merritt RM, Williams MF, James TH, Porubsky ES. Detection of cervical metastasis. A meta-analysis comparing computed tomography with physical examination. Arch Otolaryngol Head Neck Surg 1997; 123:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. J Am Acad Dermatol 2018; 78:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baum CL, Wright AC, Martinez JC, et al. A new evidence-based risk stratification system for cutaneous squamous cell carcinoma into low, intermediate, and high risk groups with implications for management. J Am Acad Dermatol 2018; 78:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys 2001; 49:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karia PS, Morgan FC, Ruiz ES, Schmults CD. Clinical and Incidental Perineural Invasion of Cutaneous Squamous Cell Carcinoma: A Systematic Review and Pooled Analysis of Outcomes Data. JAMA Dermatol 2017; 153:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jambusaria-Pahlajani A, Hess SD, Katz KA, et al. Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons. Arch Dermatol 2010; 146:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goepfert H, Dichtel WJ, Medina JE, et al. Perineural invasion in squamous cell skin carcinoma of the head and neck. Am J Surg 1984; 148:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottel WI. Perineural invasion by squamous-cell carcinoma. J Dermatol Surg Oncol 1982; 8:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendenhall WM, Parsons JT, Mendenhall NP, et al. Carcinoma of the skin of the head and neck with perineural invasion. Head Neck 1989; 11:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz ES, Karia PS, Morgan FC, Schmults CD. The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management. J Am Acad Dermatol 2017; 76:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson FT, Murad F, Granger E, et al. Perioperative imaging for high-stage cutaneous squamous cell carcinoma helps guide management in nearly a third of cases: A single-institution retrospective cohort. J Am Acad Dermatol 2023; 88:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Bondt RB, Nelemans PJ, Hofman PA, et al. Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. Eur J Radiol 2007; 64:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu LM, Xu JR, Liu MJ, et al. Value of magnetic resonance imaging for nodal staging in patients with head and neck squamous cell carcinoma: a meta-analysis. Acad Radiol 2012; 19:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginsberg LE. MR imaging of perineural tumor spread. Magn Reson Imaging Clin N Am 2002; 10:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailet JW, Abemayor E, Jabour BA, et al. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992; 102:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho SB, Chung WG, Yun M, et al. Fluorodeoxyglucose positron emission tomography in cutaneous squamous cell carcinoma: retrospective analysis of 12 patients. Dermatol Surg 2005; 31:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Land R, Herod J, Moskovic E, et al. Routine computerized tomography scanning, groin ultrasound with or without fine needle aspiration cytology in the surgical management of primary squamous cell carcinoma of the vulva. Int J Gynecol Cancer 2006; 16:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knappe M, Louw M, Gregor RT. Ultrasonography-guided fine-needle aspiration for the assessment of cervical metastases. Arch Otolaryngol Head Neck Surg 2000; 126:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Work Group, Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol 2018; 78:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984; 10:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstock MA, Bogaars HA, Ashley M, et al. Nonmelanoma skin cancer mortality. A population-based study. Arch Dermatol 1991; 127:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg 2005; 9:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozgediz D, Smith EB, Zheng J, et al. Basal cell carcinoma does metastasize. Dermatol Online J 2008; 14:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fosko SW, Hu W, Cook TF, Lowe VJ. Positron emission tomography for basal cell carcinoma of the head and neck. Arch Dermatol 2003; 139:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss GJ, Korn RL. Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors. Cancer 2012; 118:5310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thacker CA, Weiss GJ, Tibes R, et al. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Med 2012; 1:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harwood M, Wu H, Tanabe K, Bercovitch L. Metastatic basal cell carcinoma diagnosed by sentinel lymph node biopsy. J Am Acad Dermatol 2005; 53:475.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13714 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29803777" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : A 5-year follow-up study of 633 cutaneous SCC excisions: Rates of local recurrence and lymph node metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29405246" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Metastasis Risk of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients and Immunocompetent Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23375456" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18617440" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28325389" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The role of imaging in the management of patients with nonmelanoma skin cancer: When is imaging necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28325389" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The role of imaging in the management of patients with nonmelanoma skin cancer: When is imaging necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15061850" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34607849" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Metastatic zosteriform cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11391102" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Zosteriform and epidermotropic metastatic primary cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10777267" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cutaneous squamous cell carcinoma with zosteriform metastases in a human immunodeficiency virus-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10777267" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cutaneous squamous cell carcinoma with zosteriform metastases in a human immunodeficiency virus-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27598442" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : In-Transit Metastasis From Squamous Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21255868" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20870631" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Basal cell and squamous cell skin cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2293701" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Rationale for elective neck dissection in 1990.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4077554" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : False-positive and false-negative neck nodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9307901" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Imaging of nodal metastases in the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3815278" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Is modified radical neck dissection only a staging procedure?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9323149" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparison of ultrasound-fine needle aspiration and computed tomography in patients undergoing elective neck dissection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9046281" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Detection of cervical metastasis. A meta-analysis comparing computed tomography with physical examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29332705" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28917382" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A new evidence-based risk stratification system for cutaneous squamous cell carcinoma into low, intermediate, and high risk groups with implications for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11240248" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28678985" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical and Incidental Perineural Invasion of Cutaneous Squamous Cell Carcinoma: A Systematic Review and Pooled Analysis of Outcomes Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21079057" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6486325" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Perineural invasion in squamous cell skin carcinoma of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6749931" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Perineural invasion by squamous-cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2753698" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Carcinoma of the skin of the head and neck with perineural invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27707594" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36681240" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Perioperative imaging for high-stage cutaneous squamous cell carcinoma helps guide management in nearly a third of cases: A single-institution retrospective cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17391885" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22153656" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Value of magnetic resonance imaging for nodal staging in patients with head and neck squamous cell carcinoma: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12530232" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : MR imaging of perineural tumor spread.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1545657" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15871320" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Fluorodeoxyglucose positron emission tomography in cutaneous squamous cell carcinoma: retrospective analysis of 12 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16445651" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Routine computerized tomography scanning, groin ultrasound with or without fine needle aspiration cytology in the surgical management of primary squamous cell carcinoma of the vulva.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10979122" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ultrasonography-guided fine-needle aspiration for the assessment of cervical metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29331386" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Guidelines of care for the management of cutaneous squamous cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6736323" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1863078" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Nonmelanoma skin cancer mortality. A population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16208438" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Metastatic basal cell carcinoma: report of two cases and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19061565" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Basal cell carcinoma does metastasize.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12975155" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Positron emission tomography for basal cell carcinoma of the head and neck.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22511370" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23342272" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16112356" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Metastatic basal cell carcinoma diagnosed by sentinel lymph node biopsy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
